上海合珀生物科技有限公司

English

Newsroom

Stay Connected for the Latest Updates

Company News
Event Information
Industry Information

Hepabiotech and Nanjing Innovation Transformation Institute Signed an Agreement to Establish a Joint R&D Center

Hepabiotech and Nanjing Innovation Transformation Institute Signed an Agreement to Establish a Joint R&D Center

Hepabiotech and Nanjing Innovation Transformation Institute Signed an Agreement to Establish a Joint R&D Center

Hepabiotech and Nanjing Innovation Transformation Institute Signed an Agreement to Establish a Joint R&D Center

Invitation to participate the 5th Shanghai Lingang Biomedical Innovation and Development Forum

Welcome to participate the 5th Shanghai Lingang Biomedical Innovation and Development Forum. During this exhibition, Hepabiotech will set up a special area for technology display and exchange.On De...

Invitation to participate the 5th Shanghai Lingang Biomedical Innovation and Development Forum

Welcome to participate the 5th Shanghai Lingang Biomedical Innovation and Development Forum. During this exhibition, Hepabiotech will set up a special area for technology display and exchange.On De...

FDA Released a Draft Guidance Document Titled "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies."

On December 2, 2025, the U.S. FDA released a draft guidance document titled "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies." This document systematically outlines a simplified pat...

FDA Released a Draft Guidance Document Titled "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies."

On December 2, 2025, the U.S. FDA released a draft guidance document titled "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies." This document systematically outlines a simplified pat...

Linkedln

Contact Way

18616172878

pangcc@hepabio.cn

Room 214, No.781 Cailun Road, Pudong New Area, Shanghai

© 2025 Shanghai HepaBiotech Co., Ltd. All Rights Reserved.

沪ICP备2025130643号-1